Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease

NCT06924970 is registered in ClinicalTrials.gov with Agios Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06924970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06924970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
Lead sponsor
Agios Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 1, 2025
Completion date
May 31, 2027
Enrollment
59 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease